MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 13710-19-5
MCE 国际站:Tolfenamic Acid
产品活性:Tolfenamic Acid (GEA 6414) 是一种非甾体抗炎剂和抗癌剂,能够选择性地抑制 COX-2 的活性,在 LPS 诱导的犬 DH82 单核细胞/巨噬细胞中,对 COX-2 的 IC50 值为 13.49 μM (3.53 μg/mL),对 COX-1 无作用。
研究领域:Immunology/Inflammation
作用靶点:COX
In Vitro: Tolfenamic Acid (GEA 6414) is a nonsteroidal antiinflammatory agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
Tolfenamic Acid (GEA 6414) (100 μM) inhibits >70% of cell viability of BE3, OE33, and SKGT5. Tolfenamic Acid (GEA 6414) also acts as a potent Sp protein inhibitor, decreases Sp1 and Sp4 and suppresses c-Met expression in esophageal cancer cells BE3 and SKGT5.
Tolfenamic AcidTolfenamic Acid (GEA 6414) (50 μM) significantly affects gene expression in L3.6pl cells, and downregulates CENPF, KIF20A, LMNB1, MYB, SKP2, CCNE2, and DDIT3.
In Vivo: Tolfenamic Acid (GEA 6414) (50 mg/kg 3 times/wk, p.o.) inhibits tumor formation and tumor incidence in N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumor model. Tolfenamic Acid (GEA 6414) also causes decreases in tumor multiplicity and tumor volume in rats treated with NMBA.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | CNS-Penetrant Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Pyroptosis Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Pancreatic Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | Antidepressant Compound Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Non-steroidal Anti-Inflammatory Compound Library | Off-patent Drug Library | Mitochondrial Toxicity Compound Library | Highly Selective Inhibitors Library | Meloxicam-d3-1 | 4-Methylamino antipyrine hydrochloride | Vedaprofen-d3 | Pelubiprofen-13C,d3 | N-tert-Butyl-α-phenylnitrone-d14 | Tepoxalin | Ampyrone | Pectolinarigenin | Ermanin | Aceclofenac-d4 | SC-58125 | Salicylic acid-13C6 | (±)-Naproxen-d3-1 | Dehydroevodiamine hydrochloride | Aspirin-d4 | Asaraldehyde | Broussonin E | (-)-Epicatechin | COX-2/15-LOX-IN-1 | 20(S)-Ginsenoside Rg3 | Ginsenoside Rd | Salicylic acid-d6 | TFAP | Hydrangenol | Alminoprofen | Acetaminophen-d3 | FPL 62064 | Crocin II | AG-024322 | Ketoprofen-13C,d3
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。